All Sjögren’s disease articles
-
NewsNovartis scores Phase III wins for two ianalumab indications
Late-stage trials in Sjögren’s disease and primary immune thrombocytopenia met primary endpoints.
Late-stage trials in Sjögren’s disease and primary immune thrombocytopenia met primary endpoints.